Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus DIFLUPREDNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus DIFLUPREDNATE.
DERMA-SMOOTHE/FS vs DIFLUPREDNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Difluprednate is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Topical: Apply thin film to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Clinical Note
moderateDifluprednate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Gatifloxacin."
Clinical Note
moderateDifluprednate + Rosoxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Rosoxacin."
Clinical Note
moderateDifluprednate + Levofloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life approximately 2–4 hours; clinically, duration of action may extend due to receptor binding.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal (65–75% as metabolites), with biliary/fecal excretion accounting for 15–25%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Difluprednate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Trovafloxacin."